The North American marijuana stocks we’ve discovered have done exceptionally well during the month of September
SmallCapPower | October 2, 2018: September was an exciting month for the cannabis industry, as companies scrambled to grab a slice of the potential $4.3B legal market that is poised to open up in Canada on October 17, 2018. Interestingly, the big players in the industry, namely Canopy Growth Corporation (TSX:WEED), did not perform as well as some of the smaller cannabis companies in the month of September. In fact, Canopy Growth shares actually fell by nearly 9% in September, while the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ), a proxy for the industry, rose 7% during the same period. The North American marijuana stocks we’ve weeded out have all seen their share prices more than double in September.
PUF Ventures Inc. (CSE:PUF) – $1.30
PUF Ventures is a medical cannabis company operating a production facility out of London, Ontario. The Company’s stated strategy is centered around acquisitions and joint ventures to create shareholder value. PUF’s planned strains include OG Kush, Purple Kush, and Blueberry. The Company also operates Pure Grow Medicinals S.A.S. in Columbia, a wholly-owned subsidiary designed to expand PUF’s international footprint.
Aleafia Health is involved in the production and sale of cannabis products, as well as consultation services to determine the suitability of the Company’s products for treating various chronic conditions. Aleafia operates 22 referral-only medical cannabis clinics across Canada, assisting over 50,000 patients to date. In addition, the Company expects its annual cannabis production capacity to hit 38,000 kg by 2019. On September 27, 2018, Aleafia announced a supply deal with CannTrust for the sale of up to 15,000kg of cannabis in 2019. Meanwhile, the Company expects its dry flower growing capacity to reach 38,000kg sometime in 2019.
FSD Pharma Inc. (CSE:HUGE) – $0.71
FSD Pharma is in the process of transforming its primary facility in Cobourg, Ontario, into the world’s largest hydroponic cannabis production site. Hydroponics is a method of growing that does not use soil, which involves the submersion of the plant’s roots in a nutrient-rich solution. On September 26, 2018, Horizons completed its rebalancing of the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ), now holding 1.9% of its $1.1 billion of assets in FSD Pharma shares.
India Globalization Capital, Inc. (AMEX:IGC) – US$6.45
India Globalization Capital’s pharmaceutical operations involve using cannabis extracts to treat several diseases, including Alzheimer’s, chronic pain, eating disorders, Parkinson’s, and epilepsy. Established in Washington State, the Company hopes to expand its marketing of Hyalolex, a drug designed to treat symptoms of Alzheimer’s, to all Canada, Germany, and the remaining medical states in 2019. On September 5, 2018, India Globalization Capital announced plans to enter the CBD-infused beverage market. The Company also maintains an infrastructure arm involved in trading of commodities, leasing heavy equipment, and real estate management.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below: